Oppenheimer & Co. Inc. grew its position in Eli Lilly And Co (NYSE:LLY) by 3.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 60,652 shares of the company’s stock after purchasing an additional 2,162 shares during the period. Oppenheimer & Co. Inc.’s holdings in Eli Lilly And Co were worth $7,018,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Ironwood Financial llc purchased a new stake in shares of Eli Lilly And Co in the fourth quarter valued at about $30,000. Csenge Advisory Group purchased a new stake in shares of Eli Lilly And Co in the third quarter valued at about $58,000. Cornerstone Advisors Inc. raised its holdings in shares of Eli Lilly And Co by 21.3% in the third quarter. Cornerstone Advisors Inc. now owns 776 shares of the company’s stock valued at $83,000 after purchasing an additional 136 shares during the last quarter. First Command Bank increased its holdings in Eli Lilly And Co by 31.3% during the fourth quarter. First Command Bank now owns 834 shares of the company’s stock worth $96,000 after buying an additional 199 shares during the last quarter. Finally, First Command Financial Services Inc. increased its holdings in Eli Lilly And Co by 31.3% during the fourth quarter. First Command Financial Services Inc. now owns 834 shares of the company’s stock worth $96,000 after buying an additional 199 shares during the last quarter. Institutional investors own 76.83% of the company’s stock.
Shares of NYSE:LLY opened at $120.89 on Friday. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.91 and a quick ratio of 1.53. The stock has a market cap of $128.06 billion, a price-to-earnings ratio of 28.25, a price-to-earnings-growth ratio of 1.85 and a beta of 0.37. Eli Lilly And Co has a twelve month low of $73.69 and a twelve month high of $120.99.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be given a dividend of $0.645 per share. This represents a $2.58 dividend on an annualized basis and a yield of 2.13%. The ex-dividend date is Thursday, February 14th. This is a positive change from Eli Lilly And Co’s previous quarterly dividend of $0.56. Eli Lilly And Co’s dividend payout ratio (DPR) is currently 52.57%.
A number of research firms recently issued reports on LLY. Citigroup downgraded shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $113.00 price objective for the company. in a report on Sunday, December 2nd. Zacks Investment Research downgraded shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a report on Tuesday, December 4th. UBS Group began coverage on shares of Eli Lilly And Co in a report on Wednesday, January 23rd. They set a “buy” rating and a $131.00 price objective for the company. Barclays restated a “buy” rating and set a $130.00 price objective on shares of Eli Lilly And Co in a report on Sunday, January 20th. Finally, Guggenheim began coverage on shares of Eli Lilly And Co in a report on Monday, October 8th. They set a “buy” rating for the company. Ten research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $113.24.
In other Eli Lilly And Co news, major shareholder Eli & Co Lilly sold 700,000 shares of the stock in a transaction dated Tuesday, November 6th. The shares were sold at an average price of $14.00, for a total transaction of $9,800,000.00. Following the completion of the transaction, the insider now owns 3,148,647 shares in the company, valued at $44,081,058. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Myles O’neill sold 25,000 shares of the stock in a transaction dated Monday, December 10th. The stock was sold at an average price of $112.92, for a total transaction of $2,823,000.00. Following the transaction, the senior vice president now owns 26,562 shares of the company’s stock, valued at approximately $2,999,381.04. The disclosure for this sale can be found here. Insiders have sold 1,716,383 shares of company stock valued at $126,899,574 in the last quarter. Company insiders own 0.11% of the company’s stock.
Eli Lilly And Co Company Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Recommended Story: Why do corrections happen?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.